<DOC>
	<DOCNO>NCT01260610</DOCNO>
	<brief_summary>Combination therapy use nucleos ( ) ide analogues lead high viral suppression although may sustain long . Also remain unknown combination potent analogues beneficial individual drug . Thus study carry determine efficacy safety combination tenofovir plus telbivudine ( two potent nucleos ( ) ide analogue ) versus monotherapy either drug alone . This 104 week open label , prospective , randomize , multicentric study . The patient receive either tenofovir , telbivudine combination two drug . After completion 24 week , non-responders ( ie HBV-DNA &gt; 300 copies/ ml ) switch combination arm continue receive tenofovir plus telbivudine 104 week .</brief_summary>
	<brief_title>Randomized Controlled Study Tenofovir Plus Telbivudine Versus Monotherapy With Either Drug HBeAg Negative Chronic Hepatitis B Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>HBeAg negative screening Documented chronic Hepatitis B Treatment naive Compensated liver disease Chronic Hepatitis B Child Pugh B &amp; C HBeAg positive Decompensated liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Hepatitis B , Tenofovir , Telbivudine</keyword>
</DOC>